ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1116

Dual Treatment of CD40 Silencing or Mesenchymal Stem Cells Infusion with Sub-Therapeutic Doses of Cyclosporine Effectively Prevents Acute Rejection in an Allogenic Model of Renal Transplantation

Session Information

  • Transplantation: Basic
    November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

  • 1901 Transplantation: Basic


  • Guiteras, Jordi, IDIBELL, Hospitalet de Llobregat, Spain
  • De ramon, Laura, IDIBELL, Hospitalet de Llobregat, Spain
  • Bolanos, Nuria, IDIBELL, Hospitalet de Llobregat, Spain
  • Franquesa, Marcela, Hospital Germans Trias i Pujol, Badalona, Spain
  • Goma, Montse, Bellvitge Hospital, Barcelona, Spain
  • Lloberas, Nuria, IDIBELL, Hospitalet de Llobregat, Spain
  • Bestard, Oriol, Bellvitge Hospital, Barcelona, Spain
  • Grinyó, Josep maria, Bellvitge Hospital, Barcelona, Spain
  • Torras, Juan, Bellvitge Hospital, Barcelona, Spain

Previous studies in our group, showed partial protective effect of costimulatory silencing with a siRNA-CD40 or MSC infusion in life sustaining model of rat renal allograft transplant. This study was designed to investigate the combination of CD40 silencing or MSC infusion with suboptimal doses of Cyclosporine in this renal allograft model.


In this model, rats were randomly allocated into different groups: Non-Treated (n=10); Scrambled siRNA (n=10); Cyclosporine (control full dose, 5 mg/kg/day) (n=9); CsA1/2 (sub-therapeutic, 2.5 mg/kg), (n=5); MSC, group treated with two MSC doses at day -7 and day 0 (n=8); siRNA-CD40 (500 ug), (n=5); CsA1/2+siRNA-CD40 group (n=5) and CsA1/2+MSC group (n=8). Heterotopic renal transplantation was performed from Wistar to Lewis rats, with 21 days of follow up. Survival, renal function, conventional histology and immunohistochemistry (CD68 cells, CD3 cells, glomerular and peritubular capillary C4d) were analyzed in all groups.


Monotherapy either with CsA1/2, siRNA-CD40 or MSC showed slight improvement in all the studied parameters compared with Non-treated or Scrambled groups. The combined therapy using CsA1/2+MSC or CsA1/2+siRNA-CD40 displayed significant amelioration of these parameters compared to monotherapy groups. Interestingly, the CsA1/2+siRNA-CD40 group presented a clear reduction of glomerular and peritubular C4d deposition and the degree of CD3 infiltrate, reaching similar values to Cyclosporine full dose group.


In conclusion, siRNA or MSC combined with sub-therapeutic doses of Cyclosporine offered better prevention in allograft rejection and survival than monotherapy groups. But was the CsA1/2+siRNA-CD40 group that gave the greatest prevention both in the cellular and humoral arms, perhaps by an additive effect.


  • Government Support - Non-U.S.